文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

肿瘤溶解综合征、急性肾损伤与需紧急化疗重症患者的无病生存

Tumor lysis syndrome, acute kidney injury and disease-free survival in critically ill patients requiring urgent chemotherapy.
PubMed 文献 · Ann Intensive Care · 2022-02-15
一句话结论需紧急化疗的肿瘤溶解综合征患者中急性肾损伤发生率80.4%,拉布立酶使用与1年原发恶性肿瘤缓解相关,延迟化疗可能对长期结局不利。

这项2012至2018年的回顾性单中心研究纳入153例生物性和/或临床性肿瘤溶解综合征患者,主要终点为急性期急性肾损伤发生率。结果显示123例(80.4%)发生急性肾损伤,83例(54.2%)需要肾脏替代治疗;mSOFA评分(OR=1.15)、年龄(OR=1.05)和男性(OR=6.79)与急性肾损伤相关。拉布立酶使用与1年原发恶性肿瘤缓解相关(HR=2.45),机械通气、血管加压药、年龄、自发性肿瘤溶解综合征和化疗延迟与1年死亡率相关。作者认为拉布立酶可能反映高肿瘤溶解度和化疗敏感性,需更多研究证实尿酸氧化酶的保护作用。

要点

  • 153例肿瘤溶解综合征患者中123例(80.4%)发生急性肾损伤,83例(54.2%)需要肾脏替代治疗。
  • 与急性肾损伤相关的因素:mSOFA评分(OR=1.15,95%CI 1.02-1.34)、年龄(OR=1.05,95%CI 1.02-1.08)、男性(OR=6.79,95%CI 2.59-19.44)。
  • 拉布立酶使用与1年原发恶性肿瘤缓解相关(HR=2.45,95%CI 1.17-5.15)。
  • 与1年死亡率相关的因素:机械通气(HR=1.96,95%CI 1.02-3.78)、血管加压药(HR=3.13,95%CI 1.59-6.15)、年龄(HR=1.02,95%CI 1-1.03)、自发性肿瘤溶解综合征(HR=1.65,95%CI 1.01-2.69)、化疗延迟(HR=1.01,95%CI 1-1.03)。

适用人群与场景

  • 2012至2018年诊断为生物性和/或临床性肿瘤溶解综合征的患者,共153例。

研究设计与关键结果

  • 回顾性单中心研究,纳入153例肿瘤溶解综合征患者,主要终点为急性期急性肾损伤发生率。
  • 123例(80.4%)发生急性肾损伤,83例(54.2%)需要肾脏替代治疗。
  • mSOFA评分(OR=1.15,95%CI 1.02-1.34)、年龄(OR=1.05,95%CI 1.02-1.08)、男性(OR=6.79,95%CI 2.59-19.44)与急性肾损伤相关。
  • 拉布立酶使用(HR=2.45,95%CI 1.17-5.15)与1年原发恶性肿瘤缓解相关。
  • 机械通气(HR=1.96,95%CI 1.02-3.78)、血管加压药(HR=3.13,95%CI 1.59-6.15)、年龄(HR=1.02,95%CI 1-1.03)、自发性肿瘤溶解综合征(HR=1.65,95%CI 1.01-2.69)、化疗延迟(HR=1.01,95%CI 1-1.03)与1年死亡率相关。

证据类型、等级与局限

  • 证据类型:回顾性单中心研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,拉布立酶可能是高肿瘤溶解度和化疗敏感性的间接标志物,需更多研究证实尿酸氧化酶的保护作用。
  • 作者认为,延迟化疗可能对长期结局不利。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Tumor lysis syndrome (TLS) is a life-threatening complication during the treatment of malignant neoplasia. We sought to describe characteristics and predictors of acute kidney injury (AKI), remission and mortality in high-risk TLS patients. In this retrospective monocentric study, we included all patients with the diagnosis of biological and/or clinical TLS from 2012 to 2018. The primary outcome was the prevalence of AKI during the acute phase of TLS. Secondary outcomes were overall mortality and remission of the underlying malignancy at 1 year.

RESULTS: Among 153 patients with TLS, 123 (80.4%) patients experienced AKI and 83 (54.2%) required renal replacement therapy. mSOFA score (OR = 1.15, IC 95% [1.02-1.34]), age (OR = 1.05, IC 95% [1.02-1.08]) and male gender (OR = 6.79, IC 95% [2.59-19.44]) were associated with AKI. Rasburicase use (HR = 2.45, IC 95% [1.17-5.15]) was associated with remission of the underlying malignancy at 1 year. Parameters associated with mortality at 1 year were mechanical ventilation (HR = 1.96, IC 95% [1.02-3.78]), vasopressors (HR = 3.13, IC 95% [1.59-6.15]), age (HR = 1.02, IC 95% [1-1.03]), spontaneous TLS (HR = 1.65, IC 95% [1.01-2.69]) and delay of chemotherapy administration (HR = 1.01, IC 95% [1-1.03]).

CONCLUSIONS: AKI is highly prevalent in TLS patients. Rasburicase is associated with better outcomes regarding remission of the underlying malignancy. As rasburicase may be an indirect marker of a high degree of tumor lysis and chemosensitivity, more studies are warranted to confirm the protective role of urate oxidase. Delaying chemotherapy may be deleterious in terms of long-term outcomes.

来源:Ann Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Abdel-Nabey M, Chaba A, Serre J, et al. Tumor lysis syndrome, acute kidney injury and disease-free survival in critically ill patients requiring urgent chemotherapy. Ann Intensive Care. 2022. PMID: 35166948. doi:10.1186/s13613-022-00990-1

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。